

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 23 December 1999 (23.12.99)	
International application No. PCT/GB99/01417	Applicant's or agent's file reference P021625WO
International filing date (day/month/year) 06 May 1999 (06.05.99)	Priority date (day/month/year) 06 May 1998 (06.05.98)
Applicant LAWSON, Alastair, David, Griffiths et al	

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

06 December 1999 (06.12.99)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).


The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Juan Cruz
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/13, 15/62, 15/85, 5/10, C07K 14/705, 14/725, 14/73, 16/28	A1	(11) International Publication Number: WO 99/57268 (43) International Publication Date: 11 November 1999 (11.11.99)
(21) International Application Number: PCT/GB99/01417 (22) International Filing Date: 6 May 1999 (06.05.99) (30) Priority Data: 9809658.9 6 May 1998 (06.05.98) GB (71) Applicant (for all designated States except US): CELLTECH THERAPEUTICS LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): LAWSON, Alastair, David, Griffiths [GB/GB]; Holden Farm, Cheriton, Alresford, Hampshire SO2 0NX (GB). FINNEY, Helene, Margaret [GB/GB]; 64 Clare Road, Maidenhead, Berkshire SL6 4DQ (GB). (74) Agent: MERCER, Christopher, Paul; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: CHIMERIC RECEPTORS



(57) Abstract

DNA is described which codes for chimeric receptors which contain two or more independent polypeptide chains each of which contains an extra cellular ligand association domain attached to a signalling domain through a transmembrane and optionally one or more spacer domains. Each polypeptide chain can be expressed in an effector cell and will remain largely unassociated with the other(s) in the absence of ligand. The presence of ligand induces a stable interaction between the ligand association domains of each chain and facilitates interaction between the intracellular domains leading to a signalling event and activation of the cell. The activated cell may be of use in medicine for example in the treatment of diseases such as cancer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CHIMERIC RECEPTORS

5 This invention relates to chimeric receptors, to DNA coding therefor and to the use of the receptors in medicine.

Chimeric receptors have been designed to target cells such as T-cells to other cells expressing antigen on their cell surface. Binding of antigen to the receptor in the correct context triggers a series of intracellular events
10 leading to activation of the receptor bearing cell. Activation may lead to an increase in proliferation; expression of cytokines, with for example pro or anti-inflammatory responses; stimulation of cytolytic activity, differentiation or other effector functions; antibody secretion; phagocytosis; tumour infiltration and/or increased adhesion. Clearly such activation may have
15 therapeutic benefits and chimeric receptors which can facilitate this are of use in the treatment of a number of diseases or disorders.

Previously described chimeric receptors provide antigen recognition either in a single chain, for example as in a single chain, Fv or CD4, linked to an
20 intracellular signalling region [Eshhar, Z *et al*, (1993) Proc. Natl. Acad. Sci. USA 90, 720; Stancovski, I *et al* (1993) J. Immunol. 151, 6577; Hwu, P *et al*, (1993) J. Exp. Med. 178, 361; Brocker, T *et al*, (1993) Eur. J. Immunol. 23, 1435; Moritz, D. *et al* (1994) Proc. Natl. Acad. Sci. USA, 91, 4318; Roberts, M. *et al*, (1994) Blood 84, 2878; Hwu, P *et al*, (1995) Cancer
25 Res. 55, 3369; Tran, A-C *et al* (1995) J. Immunol. 155, 1000; Hekele, A *et al* (1996) Int. J. Cancer 68, 232; Altenschmidt, U *et al* (1996) Clin. Cancer Res. 2, 1001; Brocker, T *et al* (1996) Eur. J. Immunol. 26, 1770; Weitjens, M *et al* (1996) J. Immunol. 157, 836; Alvarez-Vallina, L and Hawkins, R E (1996) Eur. J. Immunol. 26, 2304], or in two chains as in V_L-
30 TCR α with V_H-TCR β or V_H-TCR α with V_L-TCR β but with no intracellular signalling sequences attached [Kuwana, Y *et al*, (1987) Biochem. Biophys. Res. Commun. 149, 960; Gross, G *et al* (1989) Proc. Natl. Acad. Sci. USA 86, 10024].

35 The mechanisms by which such receptors convert the extracellular binding event into intracellular signalling are largely unclear, and are likely to

involve clustering and association with endogenous cellular effector molecules. One disadvantage in their design is that there is no inherent mechanism to prevent constitutive activation in the absence of antigenic stimulation. This is undesirable since it can lead to inappropriate activation of a cell. Another problem with previously described chimeric receptors is that they are susceptible to signalling on binding soluble antigen. This limits their usefulness in the treatment of some disorders, for example in tumour therapy where many cell associated tumour antigens are also shed into the vascular system and can therefore induce inappropriate signalling by the chimeric receptor away from the tumour site.

The present invention provides an improved chimeric receptor which minimises constitutive activation in the absence of antigen and is less readily triggered by soluble antigen than previously described designs. In one particularly advantageous form the receptor according to the invention includes a mechanism whereby multiple signalling components can be localised on binding of antigen to act cooperatively to efficiently generate an intracellular signal.

The improved chimeric receptors according to the invention generally feature two or more polypeptide chains each of which contains an extracellular ligand association domain attached to a signalling domain through a transmembrane and optionally one or more spacer domains. The ligand association domains are capable of acting cooperatively with each other in the presence of ligand to form a ligand binding site. Each chain may be expressed so that it locates in a cell membrane with an orientation in which the association domain is extracellular and the signalling domain is intracellular. By careful selection of the ligand association domains and non-associating spacer and/or transmembrane domains each polypeptide chain can be expressed independently and will remain largely unassociated with the other(s) in the absence of ligand. The presence of ligand, especially cell surface expressed ligand induces a stable interaction between the ligand association domains, specifically stabilising a close spatial proximity of the polypeptide chains, and facilitating interaction between the intracellular signalling domains. The

signalling domains can be selected such that one forms a substrate for the other, thus increasing the efficiency of the signalling event.

5 The chimeric receptor according to the invention can be expressed in a host cell transformed with DNA coding for each polypeptide chain. Thus according to one aspect of the invention we provide DNA coding for a chimeric receptor containing two or more independent polypeptide chains each of said chains comprising in a N- to C-terminus sequence:

- (1) an extracellular ligand association domain;
 - 10 (2) a transmembrane domain; and
 - (3) one or more intracellular domains;
- provided that at least two of said domains in one chain are not naturally fused to each other.

15 For the avoidance of doubt, the term "not naturally fused" as used herein is intended to mean that two or more domains are not linked in a way which generates a polypeptide found in nature. Clearly, in this way, naturally occurring receptors are intended to be excluded from the invention. Providing that at least two domains are not naturally fused in
20 this way other domains, where desired, may be linked in a naturally occurring arrangement.

As used herein the term extracellular ligand association domain is intended to mean any oligo- or polypeptide which is capable of interacting
25 with cell surface molecules expressed on a target or host cell.

Thus the domain may be chosen to recognise a surface marker expressed on target cells associated with a disease state such as for example those associated with virally infected cells; bacterially infected cells; cancer cells,
30 such as the bombesin receptor expressed on lung tumour cells, carcinoembryonic antigen, polymorphic epithelial mucin and CD33; cell surface adhesion molecules; inflammatory cells present in autoimmune disease; or a T-cell receptor or antigen giving rise to autoimmunity.

35 Alternatively, the association ligand domain may be chosen such that it interacts with one or more of the other ligand association domains of the

chimeric receptor expressed by the host cell to achieve multiply-associated domains capable of recognising a surface marker expressed on a target cell as just described.

- 5 Particularly useful ligand association domains include parts of receptors associated with binding to cell surface associated molecules and especially include an antibody variable region (V_H or V_L) domain, a T-cell receptor variable region domain ($TCR\alpha$, $TCR\beta$, $TCR\gamma$, $TCR\delta$) or a chain selected from $CD8\alpha$, $CD8\beta$, $CD11a$, $CD11b$, $CD11c$, $CD18$, $CD29$,
10 $CD49a$, $CD49b$, $CD49c$, $CD49d$, $CD49e$, $CD49f$, $CD61$, $CD41$ or $CD51$. Fragments of these domains and chains may be used where appropriate.

- Each association domain in the chimeric receptor may be the same, although desirably the association domains are structurally different. In
15 one preferred arrangement, the domains are able to act cooperatively with each other to form a ligand binding site. Particular examples include a V_H domain paired with a V_L domain, two or more $TCR\alpha$, $TCR\beta$, $TCF\gamma$, and/or $TCR\delta$ domains, a $CD8\alpha$ or β homo- or heterodimer, $CD18$ paired with one or more of $CD11a$, b , or c , $CD29$ paired with one or more of $CD49a$, b , c ,
20 d , e , or f , and $CD61$ paired with $CD41c$ and/or $CD51$.

- In binding to the ligand each association domain moves to form a ligand binding site and in so doing establishes a close spatial proximity of the intracellular domains which form the C-terminal regions of the polypeptide
25 chains which constitute the chimeric receptor. Particularly useful ligand association domains include antibody V_H and V_L domains and fragments thereof, especially in a two chain receptor where one of the association domains is a V_H domain or a fragment thereof and the other is a V_L domain or a fragment thereof.

- 30 As used herein the term intracellular domain is intended to mean any oligo- or polypeptide which can participate in the transduction of a signal which results in direct or indirect activation of one or more intracellular messenger systems. Particular intracellular messenger systems include
35 for example one or more kinase pathways such as those involving tyrosine kinase, protein kinase C or MAP kinase; G-protein or phospholipase

mediated pathways; calcium mediated pathways; and pathways involving synthesis of a cytokine such as an interleukin e.g. IL-2, including NFAT, and cAMP mediated pathways.

- 5 Each intracellular domain may be derived from one or more naturally occurring polypeptide signalling sequences. Examples of suitable sequences include, for example sequences derived from the T-cell receptor such as all or part of the zeta, eta or epsilon chain; CD28; CD4; CD8; the γ chain of a Fc receptor; or signalling components from a
- 10 cytokine receptor e.g. interleukin, TNF and interferon receptors, a colony stimulating factor receptor e.g. GMCSF, a tyrosine kinase e.g. ZAP-70, fyn, lck, Itk and syk and binding domains thereof; an adhesion molecule e.g. LFA-1 and LFA-2, B29, MB-1, CD3 delta, CD3 gamma, CD5 or CD2.
- 15 At least one component in each intracellular domain will be capable of interacting cooperatively with one or more other components in other intracellular domains. Cooperative interaction includes for example association of two or more components to form a substrate capable of participating in one of the intracellular messenger systems described
- 20 above. Preferably however cooperative interaction means one of the components acting as a substrate for one or more others such that the substrate initiates a signalling event. This can either lead to an activation or down-regulation of signalling cascade. A particular example of this type of cooperative interaction may be obtained when one of the components in
- 25 an intracellular domain is derived from a CD4 intracellular chain containing the lck binding domain and a component in the other intracellular domain is a zeta chain derived from the T-cell receptor. Binding of ligand to the chains of the chimeric receptor causes association of lck with zeta facilitating phosphorylation of the zeta ARAM tyrosine residues, an early
- 30 event in signal generation.

The transmembrane domain in each polypeptide chain of the chimeric receptor generally serves to anchor each chain to the cell membrane of the host cell. Transmembrane domains may in general be any oligo- or

35 polypeptide and may be derived from a wide variety of sources such as all or part of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD8,

CD4, CD3 ϵ , CD45 and members of the tetraspan family e.g. CD9, CD37 a cytokine receptor, e.g. an interleukin receptor, TNF receptor, or interferon receptor, or a colony stimulating factor receptor, e.g. GMCSF.

- 5 Whatever the derivation of each transmembrane domain it will be desirably chosen or modified to minimise its constitutive association with any other domain in the chimeric receptor but to allow association of the receptor polypeptide chains when ligand is bound by one or more extracellular association domains. This reduces undesirable random
10 signal generation by ensuring that the intracellular domains only interact when ligand is bound by the extracellular association domains. This forms an important aspect of the design of the receptors of the invention.

In addition to the selection of appropriate transmembrane domains, the
15 ability of each receptor polypeptide chain to remain unassociated except in the presence of bound ligand may be enhanced by incorporating a spacer region between each extracellular association domain and transmembrane domain. Thus, according to a preferred aspect of the invention we provide DNA coding for a chimeric receptor containing two or more independent
20 polypeptide chains, each of said chains comprising in N- to C-terminus sequence:

- (1) an extracellular ligand association domain;
- (2) a spacer domain;
- (3) a transmembrane domain; and
- 25 (4) one or more intracellular domains; provided that at least two of said domains in one chain are not naturally fused to each other.

The term spacer domain as used herein generally means any oligo- or polypeptide serving to link the association and transmembrane domains in
30 each chain. Spacer domains may for example comprise up to 300 amino acids, preferably 20 to 100 amino acids and most preferably 25 to 50 amino acids.

Spacers may be derived from all or part of naturally occurring molecules
35 such as from all or part of the extracellular region of CD8, CD4 or CD28; or all or part of an antibody constant region, including the hinge region. All

or part of natural spacing components between functional parts of intracellular signalling molecules, for example spacers between ITAMS (immunoreceptor tyrosine based activation motifs) may also be used. Alternatively the spacer may be a non-naturally occurring sequence.

5

In order to minimise the constitutive association of transmembrane and/or spacer domains, non-naturally associating domains may initially be selected and/or domains may be modified to reduce association. This may be achieved by deleting, changing or otherwise modifying amino acids of naturally occurring sequences in the transmembrane and/or spacer domains which have side chains capable of covalently or non-covalently interacting with the side chains of amino acids in the other chain. Particular examples of amino acids of these types include cysteine residues, charged amino acids or amino acids such as serine or threonine within potential glycosylation sites.

10
15

The DNA according to the invention will additionally contain coding sequences for a signal component for each of the chains of the chimeric receptor to enable each chain to be transported to the host cell membrane. Each signal will be attached to the N-terminus of the association domain of each chain. The signal component may be that naturally associated with the association domain or may be derived from other sources. Examples of secretion signals include immunoglobulin signal sequences.

20
25

The signal, association, spacer, transmembrane and intracellular domains of each chain in the chimeric receptor are preferably derived from or based on human sequences.

Particularly useful DNA according to the invention is that coding for a chimeric receptor containing two independent polypeptide chains as described herein. In receptors of this type, one of the chains preferably has a ligand association domain which is a V_H domain or a fragment thereof, and the other has a ligand association domain which is a V_L domain or a fragment thereof.

30
35

DNA coding sequences for use in the invention are widely available in the literature and from databases. The DNA may be obtained from readily available DNA sources for example commercially available cDNA or cDNA libraries using standard molecular biology and/or chemistry procedures, for example by use of the polymerase chain reaction (PCR), oligonucleotide directed mutagenesis or oligonucleotide directed synthesis techniques, enzymatic cleavage or enzymatic filling in of gapped oligonucleotides. Such techniques are described by Maniatis *et al* in Molecular Cloning, Cold Spring Harbor Laboratory, New York 1989, and in particular in the Examples hereinafter.

The DNA may be used in association with a carrier. The carrier may be a vector or other carrier suitable for introduction of the DNA *ex-vivo* or *in-vivo* into target cells and/or target host cells. Examples of suitable vectors include viral vectors such as retroviruses, adenoviruses, adenoassociated viruses, EBV, and HSV, and non-viral vectors, such as liposomal vectors and vectors based on DNA condensing agents for example cationic lipids such as those described in International Patent Specifications Nos. WO96/10038, WO97/18185, WO97/25329, WO97/30170 and WO97/31934. Where appropriate, the vector may additionally include promoter/regulatory sequences and/or replication functions from viruses such as retrovirus LTRs, AAV repeats, SV40 and hCMV promoters and/or enhancers, splicing and polyadenylation signals; EBV and BK virus replication functions. Tissue specific regulatory sequences such as the TCR- α promoter, E-selectin promoter and the CD2 promoter and locus control region may also be used. Alternatively the carrier may be an antibody.

Each DNA molecule coding for a polypeptide chain of the chimeric receptor may be incorporated into different carriers as described above. Preferably however the DNA is incorporated into the same carrier. For this the DNA may be located for example on separate plasmids or may be advantageously part of a single plasmid additionally containing one or more promoter and/or regulatory sequences and or replication functions as just described. Thus the invention extends to a plasmid comprising DNA coding for a chimeric receptor according to the invention. Particularly

useful plasmids of this type include plasmid pHMF374 described in the Examples hereinafter and analogous plasmids containing other ligand association, spacer and/or transmembrane, and intracellular domains to those specified therein.

5

For ex-vivo use, the DNA of the invention may be introduced into effector cells removed from the target host using methods well known in the art e.g. transfection, transduction, biolistics, protoplast fusion, calcium phosphate precipitated DNA transformation, electroporation, cationic lipofection, or targeted liposomes. The effector cells are then reintroduced
10 into the host using standard techniques.

A wide variety of target hosts may be employed according to the present invention such as, for example, mammals and, especially, humans.

15

Examples of suitable effector cells include cells associated with the immune system such as lymphocytes e.g. cytotoxic T-lymphocytes, tumour infiltrating lymphocytes, natural killer cells, neutrophils, basophils or T-helper cells; dendritic cells, B-cells, haematopoietic stem cells, macrophages, monocytes or NK cells. The use of cytotoxic T-lymphocytes is especially preferred.
20

The DNA according to the invention is particularly suitable for in vivo administration. It may be in one preferred example in the form of a targeted carrier system in which a carrier as described above is capable of directing the DNA to a desired effector cell. Particular examples of such targeted delivery systems include targeted-naked DNA, targeted liposomes encapsulating and/or complexed with the DNA, targeted retroviral systems and targeted condensed DNA such as protamine and polylysine condensed DNA.
25
30

Targeting systems are well known in the art and include using, for example, antibodies or fragments thereof against cell surface antigens expressed on target cells in vivo such as CD8; CD16; CD4; CD3; selectins e.g. E-selectin; CD5; CD7; CD34; activation antigens e.g. CD69 and IL-
35

2R. Alternatively, other receptor - ligand interactions can be used for targeting e.g. CD4 to target HIV_{gp160} - expressing target cells.

5 In general the use of antibody targeted DNA is preferred, particularly antibody targeted naked DNA, antibody targeted condensed DNA and especially antibody targeted liposomes. Particular types of liposomes which may be used include for example pH-sensitive liposomes where linkers cleaved at low pH may be used to link the antibody to the liposome. Cationic liposomes which fuse with the cell membrane and deliver th
10 recombinant chimeric receptor DNA according to the invention directly into the cytoplasm may also be used. Liposomes for use in the invention may also have hydrophilic groups attached to their surface to increase their circulating half-life such as for example polyethylene glycol polymers. There are many examples in the art of suitable groups for attaching to
15 liposomes or other carriers; see for example International Patent Specifications Nos. WO 88/04924, WO 90/09782, WO 91, 05545, WO 91/05546, WO 93/19738, WO 94/20073 and WO 94/22429. The antibody or other targeting molecule may be linked to the DNA, condensed DNA or liposome using conventional readily available linking groups and reactive
20 functional groups in the antibody e.g. thiols, or amines and the like, and in the DNA or DNA containing materials.

Non-targeted carrier systems may also be used and in these targeted expression of the DNA is advantageous. Targeted expression of the DNA
25 may be achieved for example by using T-cell specific promoter systems such as the zeta promoter and CD2 promoter and locus control region, CD4, CD8, TCR α and TCR β promoters, cytokine promoters such as the IL2 promoter and the perforin promoter.

30 The DNA according to the invention may be used ex vivo and in a further aspect the invention provides effector cells transfected with DNA according to the invention. The effector cells may be any of those previously described above which are suitable for ex vivo use and are preferably T-cells most preferably cytotoxic T-cells.

The DNA according to the invention may take the form of a pharmaceutical composition. It may be a therapeutic or diagnostic composition and may take any suitable form suitable for administration. Preferably it will be in a form suitable for parenteral administration e.g. by
5 injection or infusion, for example by bolus injection or continuous infusion or particle mediated injection. Where the composition is for injection or infusion, it may take the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it may contain formulatory agents such as suspending, preservative, stabilising and/or dispersing agents.
10 Alternatively, the composition may be in dry form, for reconstitution before use with an appropriate sterile liquid. For particle mediated administration the DNA may be coated on particles such as microscopic gold particles.

If the composition is suitable for oral administration the formulation may
15 contain, in addition to the active ingredient, additives such as: starch - e.g. potato, maize or wheat starch or cellulose - or starch derivatives such as microcrystalline cellulose; silica; various sugars such as lactose; magnesium carbonate and/or calcium phosphate. It is desirable that, if the formulation is for oral administration it will be well tolerated by the patient's
20 digestive system. To this end, it may be desirable to include in the formulation mucus formers and resins. It may also be desirable to improve tolerance by formulating the compositions in a capsule which is insoluble in the gastric juices. It may also be preferable to include the composition in a controlled release formulation.

25 The DNA according to the invention is of use in medicine and the invention extends to a method of treatment of a human or animal subject, the method comprising administering to the subject an effective amount of a DNA delivery system described above. The exact amount to be used will
30 depend on the ages and condition of the patient, the nature of the disease or disorder and the route of administration, but may be determined using conventional means, for example by extrapolation of animal experiment derived data. In particular, for ex vivo use the number of transfected effector cells required may be established by ex vivo transfection and re-
35 introduction into an animal model of a range of effector cell numbers.

Similarly the quantity of DNA required for *in vivo* use may be established in animals using a range of DNA concentrations.

5 The DNA according to the invention may be useful in the treatment of a number of diseases or disorders. Such diseases or disorders may include those described under the general headings of infectious diseases, e.g. HIV infection; inflammatory disease/autoimmunity e.g. rheumatoid arthritis, osteoarthritis, inflammatory bowel disease; cancer; allergic/atopic diseases e.g. asthma, eczema; congenital e.g. cystic fibrosis, sickle cell
10 anaemia; dermatologic, e.g. psoriasis; neurologic, e.g. multiple sclerosis; transplants e.g. organ transplant rejection, graft-versus-host disease; metabolic/idiopathic disease e.g. diabetes.

15 The following Example illustrates the invention. In the Example the results show that the two chain chimeric receptor is not constitutively activated, in that no IL-2 was produced in the absence of target cells (HL60) or in the presence of cells not expressing specific antigen (NSO), and can be triggered to produce IL-2 only in the presence of cells expressing specific antigen (HL60 or NSO.CD33).

20

EXAMPLE

CONSTRUCTION OF CHIMERIC RECEPTOR GENES

25 Each component of the chimeric receptor was either PCR cloned or PCR assembled by standard techniques (PCR Protocols, Innis *et al* (1990) Academic Press Inc.) and sub-cloned in a cassette format into pBluescript KS+ (Stratagene), see Figure 1. Oligonucleotides (oligos) are described in Figure 2.

30 a) VI Cassette

The variable region of the light chain of the human engineered antibody, hP67 (engineered according to International Patent Specification WO91/09967) was PCR cloned with oligos S4503 and S4504. S4503 introduces a 5' Hind III site and S4504 a 3' Spe I site. The PCR product
35 was restricted with Hind III and Spe I and subcloned into pBluescript KS+.

b) **Vh Cassette**

The variable region of the heavy chain of the human engineered antibody, hP67 (engineered according to International Patent Specification WO91/0997) was PCR cloned with oligos S4501 and S4502. S4501
5 introduces a 5' Hind III site and S4502 a 3' Spe I site. The PCR product was restricted with Hind III and Spe I and subcloned into pBluescript KS+.

c) **CD8* Spacer Cassette**

The CD8* spacer cassette was PCR assembled using overlapping oligos:
10 S4881, S4882, S4883, S4884, S4885 and S4886. The PCR product was restricted with Spe I and Not I and subcloned into pBluescript KS+.

d) **CD4 TM / CD4 Cassette**

The CD4 transmembrane and intracellular components were PCR cloned
15 from human Leukocyte cDNA (Clonotech) with oligos S4499 and S4500. S4499 introduces a 5' Not I site and S4500 introduces a 3'EcoR I and Sac I site. The PCR product was restricted with Not I and Sac I and subcloned into pBluescript KS+.

20 e) **CD4 TM / TCR Zeta Cassette**

The intracellular component of TCR Zeta was PCR cloned from human Leukocyte cDNA (Clonotech) with oligos S4701 and S4700. S4701 is a long oligo which introduces both a 5' Not I site and the CD4 transmembrane component. S4700 introduces a 3' EcoR I site.

25 The PCR product was restricted with Not I and EcoR I and substituted for the CD4 TM / CD4 cassette in pBluescript KS+.

All of the above cassettes were sequenced (Applied Biosystems, Taq
30 DyeDeoxy Terminator Cycle Sequencing, Part Number 901497) in pBluescript KS+ prior to cloning into expression vectors.

These cassettes were assembled using standard Molecular Biology techniques to construct the following Separate Chain chimeric receptors
35 which when associated have the potential for human CD33 specificity.

a) VH / CD8* / CD4 TM / CD4

The VH / CD8* / CD4 TM / CD4 chimeric receptor consists of the variable region of the heavy chain of the human engineered antibody P67 linked via an extracellular spacer based upon part of human CD8 hinge to the transmembrane and intracellular components of human CD4.

The extracellular spacer consists of residues 95 to 159 of human CD8 (with the following amino acid substitution:- Cys (143) changed to Ala to remove a potential disulphide bond and Thr (117, 118 and 119) changed to Gly, Ala, Gly respectively to reduce potential negative charge) followed by a Gly residue to introduce a restriction site [Sukhatme *et al*, (1985) Cell 40, 591-597]. The CD4 transmembrane and intracellular component consists of residues 375 to 435 [Maddon *et al*, (1985) Cell, 42, 93-104].

b) VI / CD8* / CD4 TM / TCR Zeta

The VI / CD8* / CD4 TM / TCR Zeta chimeric receptor consists of the variable region of the light chain of the human engineered antibody P67 linked via an extracellular spacer based upon part of human CD8 hinge to the transmembrane and intracellular components of human CD4.

The extracellular spacer consists of residues 95 to 159 of human CD8 (with the following amino acid substitution:- Cys (143) changed to Ala to remove a potential disulphide bond and Thr (117, 118 and 119) changed to Gly, Ala, Gly respectively to reduce potential negative charge) followed by a Gly residue to introduce a restriction site [Sukhatme *et al* (1985) Cell, 40, 591-597]. The CD4 transmembrane component consists of residues 375 to 395 [Sukhatme *et al*, (1985), Cell, 40, 591-597]. The TCR Zeta intracellular component consists of residues 31 to 142 [Weissman *et al*, (1988) PNAS, 85, 9709-9713. Moingeon *et al* (1990) Eur. J. Immunol, 20, 1741-1745].

ANALYSIS OF SEPARATE CHAIN CHIMERIC RECEPTORS EXPRESSED IN JURKAT CELLS

a) Construction of expression plasmids

Chimeric receptor constructs were subcloned from pBluescript KS+ into the expression vector pEE6hCMV.ne [Bebington (1991), Methods 2, 136-

145] on a Hind III to EcoR I restriction fragment to generate plasmids pHMF367 and pHMF370 (see Figure 3). An expression vector was constructed expressing both separate chain chimeric receptor genes by subcloning a Bgl to BamH I fragment consisting of hCMV promoter, VI /
5 CD8* / CD4 TM / TCR Zeta and SV40 poly A site into the BamH I site of pHMF367. This double receptor plasmid is pHMF374 (see Figure 3).

b) **Construction of Jurkat cell lines**

Plasmids were linearised and transfected into Jurkat E6.1 cells (ECACC)
10 by electroporation using a Bio-Rad Gene Pulser. 30µg of DNA per 1×10^7 cells were given two pulses of 100v, 3µF in 1ml PBS. Cells were left to recover overnight in non-selective media before being selected and cultured in media supplemented with the antibiotic G418 at 2mg/ml. After approximately four weeks cells were ready for IL-2 production analysis.

15

c) **Analysis of antigen-specific IL-2 production**

1×10^5 Jurkat cells expressing either control plasmid, pEE6hCMV.ne (J. control) or double receptor plasmid, pHMF374 (J.VL/VH) were incubated overnight with target cells at various effector (E): target cell (T) ratios in a
20 96 well plate (Falcon) at 37°C/8% CO₂.

Target cells used were : the human myelocytic cells line, HL60 which expresses CD33 or the mouse myeloma, NSO transfected with either a control plasmid or one expressing human CD33. After 20-24 hours cells
25 were centrifuged and supernatant assayed for IL-2 (Quantikine kit, R & D Systems).

RESULTS

Figure 4 shows IL-2 production from Jurkat cells expressing VI / Vh
30 separate chain chimeric receptors challenged with CD33 positive HL60 target cells. Jurkat cells expressing a control plasmid produced no IL-2 when incubated with HL60 cells, and Jurkat transfectants expressing the separate chain chimeric receptors did not constitutively produce IL-2 in the absence of target cells. IL-2 was specifically produced from transfectants
35 on challenge with antigen bearing target cells, with the amount of IL-2 decreasing as the E : T ratio was increased.

Figure 5 shows the antigen specificity of IL-2 production from Jurkat transfectants expressing separate chain chimeric receptors. NSO cells transfected with a control plasmid failed to elicit an IL-2 response from
5 Jurkat cells expressing separate chain chimeric receptors, however on challenge with NSO cells that had been transfected with a CD33 plasmid and shown to express cell surface CD33, Jurkat transfectants expressing separate chain chimeric receptors produced IL-2.

CLAIMS

1. DNA coding for a chimeric receptor containing two or more independent polypeptide chains each of said chains comprising in a
5 N- to C-terminus sequence:
 - (1) an extracellular ligand association domain;
 - (2) a transmembrane domain; and
 - (3) one or more intracellular domains;provided that at least two of said domains in one chain are not
10 naturally fused to each other.
2. DNA according to Claim 1 wherein each extracellular ligand association domain coded for is an antibody variable region (V_H or V_L) domain, a T-cell receptor variable region domain ($TCR\alpha$, $TCR\beta$,
15 $TCR\gamma$, $TCR\delta$), $CD8\alpha$, $CD8\beta$, $CD11a$, $CD11b$, $CD11c$, $CD18$, $CD29$, $CD49a$, $CD49b$, $CD49c$, $CD49d$, $CD49e$, $CD49f$, $CD61$, $CD41$ or $CD51$ chain or a fragment thereof.
3. DNA according to Claim 2 wherein each association domain is
20 structurally different to each other.
4. DNA according to Claim 1 wherein the ligand association domains of the chimeric receptor coded for are a V_H domain paired with a V_L domain, two or more $TCR\alpha$, $TCR\beta$, $TCF\gamma$, and/or $TCR\delta$ domains, a
25 $CD8\alpha$ or β homo- or heterodimer, $CD18$ paired with one or more of $CD11a$, b , or c , $CD29$ paired with one or more of $CD49a$, b , c , d , e , or f , and $CD61$ paired with $CD41c$ and/or $CD51$.
5. DNA according to any of the preceding Claims wherein each
30 intracellular domain coded for is a naturally occurring polypeptide signalling sequence.
6. DNA according to Claim 5 wherein each signalling sequence is all or part of the zeta, eta or epsilon chain derived from the T-cell receptor; $CD28$; $CD4$; $CD8$; the γ chain of a Fc receptor; a signalling
35 component from a cytokine receptor, a colony stimulating factor

receptor, a tyrosine kinase and binding domains thereof; or an adhesion molecule.

- 5 7. DNA according to any one of Claims 1 to 6 wherein the transmembrane domain coded for is an oligo- or polypeptide derived from all or part of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD8, CD4, CD3 ϵ , CD45 and members of the tetraspan family, a cytokine receptor, or a colony stimulating factor receptor.
- 10 8. DNA according to any one of Claims 1 to 7 wherein each independent polypeptide chain coded for additionally contains a spacer domain positioned between the ligand association domain and the transmembrane domain.
- 15 9. DNA according to Claim 8 wherein each spacer domain is a polypeptide comprising 20 to 100 amino acids.
- 20 10. DNA according to any one of Claims 1 to 9 wherein each independent polypeptide chain coded for additionally has a secretion signal sequence attached to the N-terminus of the association domain of each chain.
- 25 11. DNA according to any of the preceding Claims wherein the chimeric receptor coded for has two independent polypeptide chains.
- 30 12. DNA according to Claim 11 wherein one polypeptide chain has a ligand association domain which is a V_H domain or a fragment thereof, and the other has a ligand association domain which is a V_L domain or a fragment thereof.
- 35 13. DNA according to any one of Claims 1 to 12 in association with a carrier.
14. DNA according to Claim 13 wherein the carrier is a viral vector, a liposomal vector, a cationic lipid or an antibody.

15. DNA according to Claim 13 wherein the carrier is a targeted carrier.

16. DNA according to any one of Claims 1 to 15 which is located on a plasmid.

5

17. Plasmid pHMF374 as described in Figure 3 herein.



18. An effector cell containing DNA or a plasmid according to any one of Claims 1 to 17.

10

1/7

FIG. 1

Construct cassettes cloned into pBluescript KS+

Vh / CD8* / CD4TM / CD4

529 Rec'd PCT/PTQ 06 NOV 2000

2/7

FIG. 2 OLIGONUCLEOTIDES SEQUENCES FOR
CHIMERIC RECEPTOR CONSTRUCTION

All oligos listed in the 5' to 3' orientation

S4501:CGCAAGCTTGCCGCCACCATGGAATGGAGC

S4502:TGGACTAGTTGAGGCAGAAGACACTGTCAC

S4503:CGCAAGCTTGCCGCCACCATGTCTGTCCC

S4504:TGGACTAGTCGTACGTTTTACTTCTACTTTAG

S4881:CGTGCCGGTCTTCCTGCCAGCGAAGCCCGGTGCGGGGCCAGCGCCG
CGACCACCAACACCGGCGCCACCS4882:GAGGCGGCGCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGG
CTGGACTTCGCGGCGCGCCCTGATTGTGS4883:CGCCGCTGGCCGCGCCGCCTCTGGGCGCAGGGACAGGGGGCTGCGAC
GCGATGGTGGGCGCCGGTGTGGTGGS4884:CGCTGGCAGGAAGACCGGCACGAAGTGGCTGAAGTACATGATGG
AGTTGCTCAGGGCACTAGTTG

S4885:CAACTAGTGCCCTGAGCAACTCC

S4886:CACAATCAGGGCGGCGCGAAG

S4499:CTGCAGTTCGCGGCCGCCCTGATTGTGCTGGGGGGCGTC


S4500:GCCGAGCTCCTATATGAATTCTCAAATGGGGCTACATGTCTTCTG

S4700:TATGAATTCTTAGCGAGGGGGCAGGGCCTGCATG

S4701:CTGGACTTCGCGGCCGCCCTGATTGTGCTGGGGGGCGTCGCCGGCC
TCCTGCTTTTCATTGGGCTAGGCATCTTCTTCAGAGTGAAGTTCAGCAGG
AGCGC


529 Rec'd PCT/PTC 06 NOV 2000

3/7




529 Rec'd PCT/PTC 06 NOV 2000

4/7



529 Rec'd PCT/PTG 06 NOV 2000


5/7



529 Rec'd PCT/PTC 06 NOV 2000

6/7


FIG. 4 STIMULATION OF SEPARATE CHAIN RECEPTORS WITH HL60 TARGET CELLS



529 Rec'd PCT/PTC 06 NOV 2000

7/7

FIG. 5 STIMULATION OF SEPARATE CHAIN RECEPTORS WITH NSO CELLS TRANSFECTED WITH A CONTROL PLASMID OR A CD33-EXPRESSING PLASMID



529 Rec'd PCT/PTC 06 NOV 2000

PATENT COOPERATION TREATY

PCT

09 / 67 4 7 2 2

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference P021625W0	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/GB 99/ 01417	International filing date (day/month/year) 06/05/1999	(Earliest) Priority Date (day/month/year) 06/05/1998
Applicant CELLTECH THERAPEUTICS LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☒ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

3
☐ None of the figures.

200

201

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01417

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 6	C12N15/12 C07K14/705	C12N15/13 C07K14/725
	C12N15/62 C07K14/73	C12N15/85 C07K16/28
C12N5/10		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC 6 C12N C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 23613 A (CELLTECH THERAPEUTICS LTD ;BEBBINGTON CHRISTOPHER ROBERT (GB); LAW) 3 July 1997 (1997-07-03) page 6, line 16 -page 7, line 9; claims 1-52; figures 1,2,14-17 ---	1-18
A	GROSS G ET AL: "EXPRESSION OF IMMUNOGLOBULIN-T-CELL RECEPTOR CHIMERIC MOLECULES AS FUNCTIONAL RECEPTORS WITH ANTIBODY-TYPE SPECIFICITY" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, 1 December 1989 (1989-12-01), pages 10024-10028, XP002054291 ISSN: 0027-8424 cited in the application the whole document --- -/--	1-18
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
6 October 1999		12/10/1999
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Hornig, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01417

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/13 C12N15/62 C12N15/85 C12N5/10
C07K14/705 C07K14/725 C07K14/73 C07K16/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 23613 A (CELLTECH THERAPEUTICS LTD ;BEBBINGTON CHRISTOPHER ROBERT (GB); LAW) 3 July 1997 (1997-07-03) page 6, line 16 -page 7, line 9; claims 1-52; figures 1,2,14-17 ---	1-18
A	GROSS G ET AL: "EXPRESSION OF IMMUNOGLOBULIN-T-CELL RECEPTOR CHIMERIC MOLECULES AS FUNCTIONAL RECEPTORS WITH ANTIBODY-TYPE SPECIFICITY" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, 1 December 1989 (1989-12-01), pages 10024-10028, XP002054291 ISSN: 0027-8424 cited in the application the whole document --- -/--	1-18



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

6 October 1999

Date of mailing of the international search report

12/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01417

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 24671 A (CELL GENESYS INC) 15 August 1996 (1996-08-15) the whole document ---	1-18
A	WO 96 23814 A (CELL GENESYS INC) 8 August 1996 (1996-08-08) the whole document ---	1-18
A	WO 95 02686 A (GEN HOSPITAL CORP) 26 January 1995 (1995-01-26) cited in the application the whole document ---	1-18
A	WO 93 19163 A (YEDA RES & DEV) 30 September 1993 (1993-09-30) cited in the application the whole document ---	1-18
A	WO 92 15322 A (GEN HOSPITAL CORP) 17 September 1992 (1992-09-17) cited in the application the whole document ---	1-18
A	WO 92 10591 A (CELL GENESYS INC ;UNIV CALIFORNIA (US)) 25 June 1992 (1992-06-25) cited in the application the whole document ---	1-18
P,A	WO 99 00494 A (CELLTECH THERAPEUTICS LTD ;FINNEY HELENE MARGARET (GB); LAWSON ALA) 7 January 1999 (1999-01-07) the whole document -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/01417

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9723613 A	03-07-1997	AU 1201997 A	17-07-1997
		CA 2238873 A	03-07-1997
		EP 0870019 A	14-10-1998
WO 9624671 A	15-08-1996	AU 4776196 A	27-08-1996
		CA 2221571 A	15-08-1996
		EP 0871726 A	21-10-1998
WO 9623814 A	08-08-1996	US 5712149 A	27-01-1998
		AU 4861396 A	21-08-1996
		CA 2221629 A	08-08-1996
		EP 0842194 A	20-05-1998
		US 5686281 A	11-11-1997
WO 9502686 A	26-01-1995	AU 6476798 A	02-07-1998
		AU 686646 B	12-02-1998
		AU 7314094 A	13-02-1995
		CA 2166102 A	26-01-1995
		CZ 9503408 A	14-08-1996
		EP 0804552 A	05-11-1997
		FI 960178 A	15-01-1996
		HU 74252 A	28-11-1996
		JP 9500020 T	07-01-1997
		NO 960175 A	15-03-1996
		NZ 269312 A	26-02-1998
		US 5912170 A	15-06-1999
		ZA 9405204 A	30-05-1995
WO 9319163 A	30-09-1993	AU 3924393 A	21-10-1993
		CA 2132349 A	30-09-1993
		EP 0638119 A	15-02-1995
		JP 7505282 T	15-06-1995
WO 9215322 A	17-09-1992	AU 662136 B	24-08-1995
		AU 1555992 A	06-10-1992
		AU 689289 B	26-03-1998
		AU 3032895 A	11-01-1996
		BR 9205736 A	27-09-1994
		CA 2104957 A	17-09-1992
		CZ 9301840 A	13-04-1994
		EP 0574512 A	22-12-1993
		FI 933882 A	06-09-1993
		HU 65631 A	28-07-1994
		JP 6509462 T	27-10-1994
		MX 9201002 A	01-09-1992
		NO 933169 A	04-11-1993
		NZ 241855 A	27-04-1994
		PT 100207 A	31-05-1994
		SK 95693 A	07-09-1994
		US 5851828 A	22-12-1998
		US 5912170 A	15-06-1999
		US 5843728 A	01-12-1998
WO 9210591 A	25-06-1992	AT 145428 T	15-12-1996
		AU 643109 B	04-11-1993
		AU 9172291 A	08-07-1992
		CA 2074825 A	15-06-1992
		DE 69123241 D	02-01-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/01417

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9210591 A		DE 69123241 T	17-04-1997
		DK 517895 T	07-04-1997
		EP 0517895 A	16-12-1992
		EP 0732402 A	18-09-1996
		ES 2096749 T	16-03-1997
		GR 3022538 T	31-05-1997
		US 5359046 A	25-10-1994
WO 9900494 A	07-01-1999	AU 8121098 A	19-01-1999

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01417

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 24671 A (CELL GENESYS INC) 15 August 1996 (1996-08-15) the whole document ---	1-18
A	WO 96 23814 A (CELL GENESYS INC) 8 August 1996 (1996-08-08) the whole document ---	1-18
A	WO 95 02686 A (GEN HOSPITAL CORP) 26 January 1995 (1995-01-26) cited in the application the whole document ---	1-18
A	WO 93 19163 A (YEDA RES & DEV) 30 September 1993 (1993-09-30) cited in the application the whole document ---	1-18
A	WO 92 15322 A (GEN HOSPITAL CORP) 17 September 1992 (1992-09-17) cited in the application the whole document ---	1-18
A	WO 92 10591 A (CELL GENESYS INC ;UNIV CALIFORNIA (US)) 25 June 1992 (1992-06-25) cited in the application the whole document ---	1-18
P,A	WO 99 00494 A (CELLTECH THERAPEUTICS LTD ;FINNEY HELENE MARGARET (GB); LAWSON ALA) 7 January 1999 (1999-01-07) the whole document -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/01417

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9723613 A	03-07-1997	AU 1201997 A	17-07-1997
		CA 2238873 A	03-07-1997
		EP 0870019 A	14-10-1998
WO 9624671 A	15-08-1996	AU 4776196 A	27-08-1996
		CA 2221571 A	15-08-1996
		EP 0871726 A	21-10-1998
WO 9623814 A	08-08-1996	US 5712149 A	27-01-1998
		AU 4861396 A	21-08-1996
		CA 2221629 A	08-08-1996
		EP 0842194 A	20-05-1998
		US 5686281 A	11-11-1997
WO 9502686 A	26-01-1995	AU 6476798 A	02-07-1998
		AU 686646 B	12-02-1998
		AU 7314094 A	13-02-1995
		CA 2166102 A	26-01-1995
		CZ 9503408 A	14-08-1996
		EP 0804552 A	05-11-1997
		FI 960178 A	15-01-1996
		HU 74252 A	28-11-1996
		JP 9500020 T	07-01-1997
		NO 960175 A	15-03-1996
		NZ 269312 A	26-02-1998
		US 5912170 A	15-06-1999
		ZA 9405204 A	30-05-1995
WO 9319163 A	30-09-1993	AU 3924393 A	21-10-1993
		CA 2132349 A	30-09-1993
		EP 0638119 A	15-02-1995
		JP 7505282 T	15-06-1995
WO 9215322 A	17-09-1992	AU 662136 B	24-08-1995
		AU 1555992 A	06-10-1992
		AU 689289 B	26-03-1998
		AU 3032895 A	11-01-1996
		BR 9205736 A	27-09-1994
		CA 2104957 A	17-09-1992
		CZ 9301840 A	13-04-1994
		EP 0574512 A	22-12-1993
		FI 933882 A	06-09-1993
		HU 65631 A	28-07-1994
		JP 6509462 T	27-10-1994
		MX 9201002 A	01-09-1992
		NO 933169 A	04-11-1993
		NZ 241855 A	27-04-1994
		PT 100207 A	31-05-1994
		SK 95693 A	07-09-1994
		US 5851828 A	22-12-1998
		US 5912170 A	15-06-1999
		US 5843728 A	01-12-1998
WO 9210591 A	25-06-1992	AT 145428 T	15-12-1996
		AU 643109 B	04-11-1993
		AU 9172291 A	08-07-1992
		CA 2074825 A	15-06-1992
		DE 69123241 D	02-01-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/01417

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9210591 A		DE 69123241 T	17-04-1997
		DK 517895 T	07-04-1997
		EP 0517895 A	16-12-1992
		EP 0732402 A	18-09-1996
		ES 2096749 T	16-03-1997
		GR 3022538 T	31-05-1997
		US 5359046 A	25-10-1994
WO 9900494 A	07-01-1999	AU 8121098 A	19-01-1999

PCT

REC'D 18 AUG 2000

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P021625WO	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB99/01417	International filing date (day/month/year) 06/05/1999	Priority date (day/month/year) 06/05/1998
International Patent Classification (IPC) or national classification and IPC C12N15/12		
Applicant CELLTECH THERAPEUTICS LIMITED et al.		



1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 06/12/1999	Date of completion of this report 14.08.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Vollbach, S Telephone No. +49 89 2399 8715 

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB99/01417

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.)*:

Description, pages:

1-16 as originally filed

Claims, No.:

1-18 as originally filed

Drawings, sheets:

1/7-7/7 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB99/01417

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	17
	No:	Claims	1-16, 18
Inventive step (IS)	Yes:	Claims	
	No:	Claims	17
Industrial applicability (IA)	Yes:	Claims	1-18
	No:	Claims	

2. Citations and explanations

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB99/01417

1. The present application relates to DNA sequences encoding two or more independent polypeptide chains of chimeric receptors comprising an extracellular ligand association domain, a transmembrane domain and one or more intracellular domains and effector cells containing these chimeric receptors.
2. Although various documents cited in the search report are relevant for the claimed subject-matter, in the present communication it is only referred to the following documents:

D1: WO 97 23613 A (CELLTECH THERAPEUTICS LTD ;BEBBINGTON
CHRISTOPHER ROBERT (GB); LAW) 3 July 1997 (1997-07-03)

D2: GROSS G ET AL: 'EXPRESSION OF IMMUNOGLOBULIN-T-CELL
RECEPTOR CHIMERIC MOLECULES AS FUNCTIONAL RECEPTORS
WITH ANTIBODY-TYPE SPECIFICITY' PROCEEDINGS OF THE
NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, 1 December 1989
(1989-12-01), pages 10024-10028, XP002054291 ISSN: 0027-8424 cited in
the application

D1 and D2 relate to the production of chimeric receptors by using DNA constructs encoding independent polypeptides composed of the domains mentioned in claim 1 of the present application. In addition upon expression homodimers or heterodimers are formed to produce a functional receptor.

Thus in view of said documents present claim 1 is no longer new. As far as the dependent claims are concerned they are also described in at least D1. Therefore also present claims 2-16 and 18 are not new as required by Article 33(2) PCT. It should be taken into account that in the search report several documents are cited which are also relevant for the assessment of novelty. They may become relevant in a later phase of the present proceedings. Should the applicant be of the opinion that claims 1 differs from the cited prior art in that the DNA encoding the independent chains are located on one vector, he is made aware that this difference is not included in the claims.

However, even if it was included in the claims, an inventive step for said claims would have to be denied, because this is an obvious modification contemplated by a person skilled in the art. In any case this difference certainly cannot confer novelty to the effector cell according to claim 18.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB99/01417

3. In summary, claims 1-16 and 18 lack novelty and claim 17 is not considered to involve an inventive step (Article 33(2) and 33(3) PCT).

PATENT COOPERATION TREATY

09 / 67 4722

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

Mercer, Ch.P.
CARPMAELS & RANSFORD
43 Bloomsbury Square
London WC1A 2RA
GRANDE BRETAGNE

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT
(PCT Rule 71.1)

WMS
Date of mailing
(day/month/year)

14.08.2000

Applicant's or agent's file reference
P021625WO

IMPORTANT NOTIFICATION

International application No.
PCT/GB99/01417

International filing date (day/month/year)
06/05/1999

Priority date (day/month/year)
06/05/1998

Applicant
CELLTECH THERAPEUTICS LIMITED et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

 European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Vullo, C

Tel. +49 89 2399-8061



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P021625WO		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/GB99/01417	International filing date (day/month/year) 06/05/1999	Priority date (day/month/year) 06/05/1998
International Patent Classification (IPC) or national classification and IPC C12N15/12		
Applicant CELLTECH THERAPEUTICS LIMITED et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 5 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 06/12/1999	Date of completion of this report 14.08.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Vollbach, S Telephone No. +49 89 2399 8715 <div data-bbox="1372 1837 1518 1974" data-label="Image"> </div>

• •

• •

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB99/01417

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.)*:

Description, pages:

1-16 as originally filed

Claims, No.:

1-18 as originally filed

Drawings, sheets:

1/7-7/7 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB99/01417

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	17
	No:	Claims	1-16,18
Inventive step (IS)	Yes:	Claims	
	No:	Claims	17
Industrial applicability (IA)	Yes:	Claims	1-18
	No:	Claims	

2. Citations and explanations

see separate sheet

2

3

4

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB99/01417

1. The present application relates to DNA sequences encoding two or more independent polypeptide chains of chimeric receptors comprising an extracellular ligand association domain, a transmembrane domain and one or more intracellular domains and effector cells containing these chimeric receptors.

2. Although various documents cited in the search report are relevant for the claimed subject-matter, in the present communication it is only referred to the following documents:

D1: WO 97 23613 A (CELLTECH THERAPEUTICS LTD ;BEBBINGTON
CHRISTOPHER ROBERT (GB); LAW) 3 July 1997 (1997-07-03)

D2: GROSS G ET AL: 'EXPRESSION OF IMMUNOGLOBULIN-T-CELL
RECEPTOR CHIMERIC MOLECULES AS FUNCTIONAL RECEPTORS
WITH ANTIBODY-TYPE SPECIFICITY' PROCEEDINGS OF THE
NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, 1 December 1989
(1989-12-01), pages 10024-10028, XP002054291 ISSN: 0027-8424 cited in
the application

D1 and D2 relate to the production of chimeric receptors by using DNA constructs encoding independent polypeptides composed of the domains mentioned in claim 1 of the present application. In addition upon expression homodimers or heterodimers are formed to produce a functional receptor.

Thus in view of said documents present claim 1 is no longer new. As far as the dependent claims are concerned they are also described in at least D1. Therefore also present claims 2-16 and 18 are not new as required by Article 33(2) PCT. It should be taken into account that in the search report several documents are cited which are also relevant for the assessment of novelty. They may become relevant in a later phase of the present proceedings. Should the applicant be of the opinion that claims 1 differs from the cited prior art in that the DNA encoding the independent chains are located on one vector, he is made aware that this difference is not included in the claims.

However, even if it was included in the claims, an inventive step for said claims would have to be denied, because this is an obvious modification contemplated by a person skilled in the art. In any case this difference certainly cannot confer novelty to the effector cell according to claim 18.

2

1

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB99/01417


3. In summary, claims 1-16 and 18 lack novelty and claim 17 is not considered to involve an inventive step (Article 33(2) and 33(3) PCT).

DUE: 18-5-00

PATENT COOPERATION TREATY

09/674722

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY



To:

Mercer, Ch.P.
CARPMAELS & RANSFORD
43 Bloomsbury Square
London WC1A 2RA
GRANDE BRETAGNE

WRITTEN OPINION

(PCT Rule 66)

Date of mailing (day/month/year)		18.02.2000
Applicant's or agent's file reference P021625WO		REPLY DUE within 3 month(s) from the above date of mailing
International application No. PCT/GB99/01417	International filing date (day/month/year) 06/05/1999	Priority date (day/month/year) 06/05/1998
International Patent Classification (IPC) or both national classification and IPC C12N15/12		
Applicant CELLTECH THERAPEUTICS LIMITED et al.		



- This written opinion is the **first** drawn up by this International Preliminary Examining Authority.
- This opinion contains indications relating to the following items:
 - ☒ Basis of the opinion
 - ☐ Priority
 - ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
 - ☐ Lack of unity of invention
 - ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
 - ☐ Certain document cited
 - ☐ Certain defects in the international application
 - ☐ Certain observations on the international application
- The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also: For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.
- The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 06/09/2000.

Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer / Examiner Vollbach, S Formalities officer (incl. extension of time limits) Vullo, C Telephone No. +49 89 2399 8730	
---	--	---

I. Basis of the opinion

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed"*):

Description, pages:

1-16 as originally filed

Claims, No.:

1-18 as originally filed

Drawings, sheets:

1/7-7/7 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-16,18
Inventive step (IS)	Claims	17
Industrial applicability (IA)	Claims	

2. Citations and explanations

see separate sheet

1. The present application relates to DNA sequences encoding two or more independent polypeptide chains of chimeric receptors comprising an extracellular ligand association domain, a transmembrane domain and one or more intracellular domains and effector cells containing these chimeric receptors.

2. Although various documents cited in the search report are relevant for the claimed subject-matter, in the present communication it is only referred to the following documents:

D1: WO 97 23613 A (CELLTECH THERAPEUTICS LTD ;BEBBINGTON
CHRISTOPHER ROBERT (GB); LAW) 3 July 1997 (1997-07-03)

D2: GROSS G ET AL: 'EXPRESSION OF IMMUNOGLOBULIN-T-CELL
RECEPTOR CHIMERIC MOLECULES AS FUNCTIONAL RECEPTORS
WITH ANTIBODY-TYPE SPECIFICITY' PROCEEDINGS OF THE
NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, 1 December 1989
(1989-12-01), pages 10024-10028, XP002054291 ISSN: 0027-8424 cited in
the application

D1 and D2 relate to the production of chimeric receptors by using DNA constructs encoding independent polypeptides composed of the domains mentioned in claim 1 of the present application. In addition upon expression homodimers or heterodimers are formed to produce a functional receptor.

Thus in view of said documents present claim 1 is no longer new. As far as the dependent claims are concerned they are also described in at least D1. Therefore also present claims 2-16 and 18 are not new as required by Article 33(2) PCT. It should be taken into account that in the search report several documents are cited which are also relevant for the assessment of novelty. They may become relevant in a later phase of the present proceedings. Should the applicant be of the opinion that claims 1 differs from the cited prior art in that the DNA encoding the independent chains are located on one vector, he is made aware that this difference is not included in the claims.

However, even if it was included in the claims, an inventive step for said claims would have to be denied, because this is an obvious modification contemplated by a person skilled in the art. In any case this difference certainly cannot confer novelty to the effector cell according to claim 18.

**WRITTEN OPINION
SEPARATE SHEET**

International application No. PCT/GB99/01417

3. In summary, claims 1-16 and 18 lack novelty and claim 17 is not considered to involve an inventive step (Article 33(2) and 33() PCT.



✉ EPA/EPO/OEB
D-80298 München
☎ +49 89 2399-0
TX 523 656 epmu d
FAX +49 89 2399-4465

**Europäisches
Patentamt**

Generaldirektion 2

**European
Patent Office**

Directorate General 2

**Office européen
des brevets**

Direction Générale 2

Correspondence with the EPO on PCT Chapter II demands

In order to ensure that your PCT Chapter II demand is dealt with as promptly as possible you are requested to use the enclosed self-adhesive labels with any correspondence relating to the demand sent to the Munich Office.

One of these labels should be affixed to a prominent place in the upper part of the letter or form etc. which you are filing.

4

5